Loading…
Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial
AIMS: Vericiguat reduced the primary composite outcome of cardiovascular death or heart failure (HF) hospitalization in patients with worsening HF with reduced ejection fraction (HFrEF) and a lower limit of baseline estimated glomerular filtration rate (eGFR) of 15 mL/min/1.73 m(2). We evaluated the...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Online Article Text |
Language: | English |
Published: |
John Wiley & Sons, Ltd.
2021
|
Subjects: | |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453520/ https://www.ncbi.nlm.nih.gov/pubmed/33999486 http://dx.doi.org/10.1002/ejhf.2221 |